Pharmacokinetics & Pharmacogenetics Studies

The SMARTc unit is dedicated to drive PK and PK/PD studies in oncology, ranging from study design using CRM-based approaches, use of constraint-models or sophisticated algorithms. Beyond study design, the SMARTc unit can provide full bioanalytical support and data management. The SMARTc has set up the two first Phase I/II clinical trials entirely driven by a mathematical model, in breast cancer and in lung cancer respectively.

In addition, the SMARTc unit develops biomarker-based studies and pharmacogenetics studies aiming at identifying predictive markers for efficacy/toxicity in relation with impaired pharmacokinetics, especially with cytotoxics.

PK PGx Ciccolini

 

PK PGx Fanciullino

Leave A Reply

Phone: +33(0)491835509
Marseille 13005
Faculté de Pharmacie